APO Research
Talk to an analyst

APO RESEARCH · REPORT

Second-Generation Antipsychotics

Compare research editions
View pricing & licenses

Selected research

Industry Research

Second-Generation Antipsychotics Industry Research Report 2026

23 December 2025148 pages

Choose your research edition.

Industry ResearchSecond-Generation Antipsychotics Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Second-Generation Antipsychotics Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Second-Generation Antipsychotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Second-Generation Antipsychotics Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Second-Generation Antipsychotics Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Second-Generation Antipsychotics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Second-Generation Antipsychotics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Second-Generation Antipsychotics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Second-Generation Antipsychotics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Second-Generation Antipsychotics include Chia Tai Tianqing Pharmaceutical, Yangtze River Pharmaceutical Group, CSPC Pharmaceutical Group, Qilu Pharmaceutical, Novartis, Merck, Luye Pharma Group, Roche and Livzon Pharmaceutical Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Second-Generation Antipsychotics market in terms of revenue (US$ million) and, where applicable, sales volume (units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Second-Generation Antipsychotics Market by Company

Chia Tai Tianqing Pharmaceutical

Yangtze River Pharmaceutical Group

CSPC Pharmaceutical Group

Qilu Pharmaceutical

Novartis

Merck

Luye Pharma Group

Roche

Livzon Pharmaceutical Group

Eli Lilly

Chengdu Kanghong Pharmaceutical

Pfizer

Hansoh Pharma

Hisun Pharmaceutical

Nhwa Pharmaceutical

AbbVie

Sumitomo Dainippon Pharma

Otsuka Pharmaceutical

Johnson And Johnson

Ipsen

Second-Generation Antipsychotics Segment by Type

Selective Dopamine Receptor Antagonists

Multi Receptor Acting Drugs

Dopamine Receptor Partial Agonists

5-Hydroxytryptamine And Dopamine Receptor Antagonists

Second-Generation Antipsychotics Segment by Application

Adjuvant Treatment For Depression

Bipolar Disorder

Schizophrenia

Other Mental Illnesses

Second-Generation Antipsychotics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Second-Generation Antipsychotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Second-Generation Antipsychotics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Second-Generation Antipsychotics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Second-Generation Antipsychotics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Second-Generation Antipsychotics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Second-Generation Antipsychotics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Second-Generation Antipsychotics Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Second-Generation Antipsychotics Sales (units) of Manufacturers (2021-2026) Table 7. Global Second-Generation Antipsychotics Sales Market Share by Manufacturers (2021-2026) Table 8. Global Second-Generation Antipsychotics Revenue of Manufacturers (2021-2026) Table 9. Global Second-Generation Antipsychotics Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Second-Generation Antipsychotics Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global Second-Generation Antipsychotics Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Second-Generation Antipsychotics, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Second-Generation Antipsychotics, Product Type & Application Table 14. Global Second-Generation Antipsychotics Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Second-Generation Antipsychotics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Chia Tai Tianqing Pharmaceutical Company Information Table 19. Chia Tai Tianqing Pharmaceutical Business Overview Table 20. Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 22. Chia Tai Tianqing Pharmaceutical Recent Developments Table 23. Yangtze River Pharmaceutical Group Company Information Table 24. Yangtze River Pharmaceutical Group Business Overview Table 25. Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio Table 27. Yangtze River Pharmaceutical Group Recent Developments Table 28. CSPC Pharmaceutical Group Company Information Table 29. CSPC Pharmaceutical Group Business Overview Table 30. CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. CSPC Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio Table 32. CSPC Pharmaceutical Group Recent Developments Table 33. Qilu Pharmaceutical Company Information Table 34. Qilu Pharmaceutical Business Overview Table 35. Qilu Pharmaceutical Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Qilu Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 37. Qilu Pharmaceutical Recent Developments Table 38. Novartis Company Information Table 39. Novartis Business Overview Table 40. Novartis Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Novartis Second-Generation Antipsychotics Product Portfolio Table 42. Novartis Recent Developments Table 43. Merck Company Information Table 44. Merck Business Overview Table 45. Merck Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Merck Second-Generation Antipsychotics Product Portfolio Table 47. Merck Recent Developments Table 48. Luye Pharma Group Company Information Table 49. Luye Pharma Group Business Overview Table 50. Luye Pharma Group Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Luye Pharma Group Second-Generation Antipsychotics Product Portfolio Table 52. Luye Pharma Group Recent Developments Table 53. Roche Company Information Table 54. Roche Business Overview Table 55. Roche Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. Roche Second-Generation Antipsychotics Product Portfolio Table 57. Roche Recent Developments Table 58. Livzon Pharmaceutical Group Company Information Table 59. Livzon Pharmaceutical Group Business Overview Table 60. Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Livzon Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio Table 62. Livzon Pharmaceutical Group Recent Developments Table 63. Eli Lilly Company Information Table 64. Eli Lilly Business Overview Table 65. Eli Lilly Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Eli Lilly Second-Generation Antipsychotics Product Portfolio Table 67. Eli Lilly Recent Developments Table 68. Chengdu Kanghong Pharmaceutical Company Information Table 69. Chengdu Kanghong Pharmaceutical Business Overview Table 70. Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 72. Chengdu Kanghong Pharmaceutical Recent Developments Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Pfizer Second-Generation Antipsychotics Product Portfolio Table 77. Pfizer Recent Developments Table 78. Hansoh Pharma Company Information Table 79. Hansoh Pharma Business Overview Table 80. Hansoh Pharma Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Hansoh Pharma Second-Generation Antipsychotics Product Portfolio Table 82. Hansoh Pharma Recent Developments Table 83. Hisun Pharmaceutical Company Information Table 84. Hisun Pharmaceutical Business Overview Table 85. Hisun Pharmaceutical Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Hisun Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 87. Hisun Pharmaceutical Recent Developments Table 88. Nhwa Pharmaceutical Company Information Table 89. Nhwa Pharmaceutical Business Overview Table 90. Nhwa Pharmaceutical Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Nhwa Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 92. Nhwa Pharmaceutical Recent Developments Table 93. AbbVie Company Information Table 94. AbbVie Business Overview Table 95. AbbVie Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. AbbVie Second-Generation Antipsychotics Product Portfolio Table 97. AbbVie Recent Developments Table 98. Sumitomo Dainippon Pharma Company Information Table 99. Sumitomo Dainippon Pharma Business Overview Table 100. Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product Portfolio Table 102. Sumitomo Dainippon Pharma Recent Developments Table 103. Otsuka Pharmaceutical Company Information Table 104. Otsuka Pharmaceutical Business Overview Table 105. Otsuka Pharmaceutical Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Otsuka Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 107. Otsuka Pharmaceutical Recent Developments Table 108. Johnson And Johnson Company Information Table 109. Johnson And Johnson Business Overview Table 110. Johnson And Johnson Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Johnson And Johnson Second-Generation Antipsychotics Product Portfolio Table 112. Johnson And Johnson Recent Developments Table 113. Ipsen Company Information Table 114. Ipsen Business Overview Table 115. Ipsen Second-Generation Antipsychotics Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Ipsen Second-Generation Antipsychotics Product Portfolio Table 117. Ipsen Recent Developments Table 118. Global Second-Generation Antipsychotics Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global Second-Generation Antipsychotics Sales by Region (2021-2026) & (units) Table 120. Global Second-Generation Antipsychotics Sales Market Share by Region (2021-2026) Table 121. Global Second-Generation Antipsychotics Sales by Region (2027-2032) & (units) Table 122. Global Second-Generation Antipsychotics Sales Market Share by Region (2027-2032) Table 123. Global Second-Generation Antipsychotics Revenue by Region (2021-2026) & (US$ Million) Table 124. Global Second-Generation Antipsychotics Revenue Market Share by Region (2021-2026) Table 125. Global Second-Generation Antipsychotics Revenue by Region (2027-2032) & (US$ Million) Table 126. Global Second-Generation Antipsychotics Revenue Market Share by Region (2027-2032) Table 127. North America Second-Generation Antipsychotics Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America Second-Generation Antipsychotics Sales by Country (2021-2026) & (units) Table 129. North America Second-Generation Antipsychotics Sales by Country (2027-2032) & (units) Table 130. North America Second-Generation Antipsychotics Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Second-Generation Antipsychotics Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe Second-Generation Antipsychotics Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe Second-Generation Antipsychotics Sales by Country (2021-2026) & (units) Table 134. Europe Second-Generation Antipsychotics Sales by Country (2027-2032) & (units) Table 135. Europe Second-Generation Antipsychotics Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Second-Generation Antipsychotics Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific Second-Generation Antipsychotics Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific Second-Generation Antipsychotics Sales by Country (2021-2026) & (units) Table 139. Asia Pacific Second-Generation Antipsychotics Sales by Country (2027-2032) & (units) Table 140. Asia Pacific Second-Generation Antipsychotics Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific Second-Generation Antipsychotics Revenue by Country (2027-2032) & (US$ Million) Table 142. South America Second-Generation Antipsychotics Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America Second-Generation Antipsychotics Sales by Country (2021-2026) & (units) Table 144. South America Second-Generation Antipsychotics Sales by Country (2027-2032) & (units) Table 145. South America Second-Generation Antipsychotics Revenue by Country (2021-2026) & (US$ Million) Table 146. South America Second-Generation Antipsychotics Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Second-Generation Antipsychotics Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa Second-Generation Antipsychotics Sales by Country (2021-2026) & (units) Table 149. Middle East and Africa Second-Generation Antipsychotics Sales by Country (2027-2032) & (units) Table 150. Middle East and Africa Second-Generation Antipsychotics Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Second-Generation Antipsychotics Revenue by Country (2027-2032) & (US$ Million) Table 152. Global Second-Generation Antipsychotics Sales by Type (2021-2026) & (units) Table 153. Global Second-Generation Antipsychotics Sales by Type (2027-2032) & (units) Table 154. Global Second-Generation Antipsychotics Sales Market Share by Type (2021-2026) Table 155. Global Second-Generation Antipsychotics Sales Market Share by Type (2027-2032) Table 156. Global Second-Generation Antipsychotics Revenue by Type (2021-2026) & (US$ Million) Table 157. Global Second-Generation Antipsychotics Revenue by Type (2027-2032) & (US$ Million) Table 158. Global Second-Generation Antipsychotics Revenue Market Share by Type (2021-2026) Table 159. Global Second-Generation Antipsychotics Revenue Market Share by Type (2027-2032) Table 160. Global Second-Generation Antipsychotics Price by Type (2021-2026) & (USD/unit) Table 161. Global Second-Generation Antipsychotics Price by Type (2027-2032) & (USD/unit) Table 162. Global Second-Generation Antipsychotics Sales by Application (2021-2026) & (units) Table 163. Global Second-Generation Antipsychotics Sales by Application (2027-2032) & (units) Table 164. Global Second-Generation Antipsychotics Sales Market Share by Application (2021-2026) Table 165. Global Second-Generation Antipsychotics Sales Market Share by Application (2027-2032) Table 166. Global Second-Generation Antipsychotics Revenue by Application (2021-2026) & (US$ Million) Table 167. Global Second-Generation Antipsychotics Revenue by Application (2027-2032) & (US$ Million) Table 168. Global Second-Generation Antipsychotics Revenue Market Share by Application (2021-2026) Table 169. Global Second-Generation Antipsychotics Revenue Market Share by Application (2027-2032) Table 170. Global Second-Generation Antipsychotics Price by Application (2021-2026) & (USD/unit) Table 171. Global Second-Generation Antipsychotics Price by Application (2027-2032) & (USD/unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Second-Generation Antipsychotics Distributors List Table 175. Second-Generation Antipsychotics Customers List Table 176. Second-Generation Antipsychotics Industry Trends Table 177. Second-Generation Antipsychotics Industry Drivers Table 178. Second-Generation Antipsychotics Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Second-Generation Antipsychotics Product Image Figure 5. Global Second-Generation Antipsychotics Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Second-Generation Antipsychotics Market Size (2021-2032) & (US$ Million) Figure 7. Global Second-Generation Antipsychotics Sales (2021-2032) & (units) Figure 8. Global Second-Generation Antipsychotics Average Price (USD/unit) & (2021-2032) Figure 9. Selective Dopamine Receptor Antagonists Product Image Figure 10. Multi Receptor Acting Drugs Product Image Figure 11. Dopamine Receptor Partial Agonists Product Image Figure 12. 5-Hydroxytryptamine And Dopamine Receptor Antagonists Product Image Figure 13. Adjuvant Treatment For Depression Product Image Figure 14. Bipolar Disorder Product Image Figure 15. Schizophrenia Product Image Figure 16. Other Mental Illnesses Product Image Figure 17. Global Second-Generation Antipsychotics Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Second-Generation Antipsychotics, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Second-Generation Antipsychotics Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Second-Generation Antipsychotics Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Second-Generation Antipsychotics Sales by Region in 2025 Figure 23. Global Second-Generation Antipsychotics Revenue by Region in 2025 Figure 24. North America Second-Generation Antipsychotics Market Size by Country in 2025 Figure 25. North America Second-Generation Antipsychotics Sales Market Share by Country (2021-2032) Figure 26. North America Second-Generation Antipsychotics Revenue Market Share by Country (2021-2032) Figure 27. United States Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Second-Generation Antipsychotics Market Size by Country in 2025 Figure 31. Europe Second-Generation Antipsychotics Sales Market Share by Country (2021-2032) Figure 32. Europe Second-Generation Antipsychotics Revenue Market Share by Country (2021-2032) Figure 33. Germany Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Second-Generation Antipsychotics Market Size by Country in 2025 Figure 44. Asia Pacific Second-Generation Antipsychotics Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Second-Generation Antipsychotics Revenue Market Share by Country (2021-2032) Figure 46. China Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Second-Generation Antipsychotics Market Size by Country in 2025 Figure 55. South America Second-Generation Antipsychotics Sales Market Share by Country (2021-2032) Figure 56. South America Second-Generation Antipsychotics Revenue Market Share by Country (2021-2032) Figure 57. Brazil Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Second-Generation Antipsychotics Market Size by Country in 2025 Figure 61. Middle East and Africa Second-Generation Antipsychotics Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Second-Generation Antipsychotics Revenue Market Share by Country (2021-2032) Figure 63. Egypt Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Second-Generation Antipsychotics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Second-Generation Antipsychotics Sales Market Share by Type (2021-2032) Figure 69. Global Second-Generation Antipsychotics Revenue Market Share by Type (2021-2032) Figure 70. Global Second-Generation Antipsychotics Price (USD/unit) by Type (2021-2032) Figure 71. Global Second-Generation Antipsychotics Sales Market Share by Application (2021-2032) Figure 72. Global Second-Generation Antipsychotics Revenue Market Share by Application (2021-2032) Figure 73. Global Second-Generation Antipsychotics Price (USD/unit) by Application (2021-2032) Figure 74. Second-Generation Antipsychotics Value Chain Figure 75. Second-Generation Antipsychotics Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Second-Generation Antipsychotics Industry Opportunities and Challenges

Scope & coverage.

Types
  • Selective Dopamine Receptor Antagonists
  • Multi Receptor Acting Drugs
  • Dopamine Receptor Partial Agonists
  • 5-Hydroxytryptamine And Dopamine Receptor Antagonists
Applications
  • Adjuvant Treatment For Depression
  • Bipolar Disorder
  • Schizophrenia
  • Other Mental Illnesses
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Yangtze River Pharmaceutical Group
  • CSPC Pharmaceutical Group
  • Qilu Pharmaceutical
  • Novartis
  • Merck
  • Luye Pharma Group
  • Roche
  • Livzon Pharmaceutical Group
  • Eli Lilly
  • Chengdu Kanghong Pharmaceutical
  • Pfizer
  • Hansoh Pharma
  • Hisun Pharmaceutical
  • Nhwa Pharmaceutical
  • AbbVie
  • Sumitomo Dainippon Pharma
  • Otsuka Pharmaceutical
  • Johnson And Johnson
  • Ipsen

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Second-Generation Antipsychotics Market Size (2021-2032)
  4. 2.2.2 Global Second-Generation Antipsychotics Sales (2021-2032)
  5. 2.2.3 Global Second-Generation Antipsychotics Market Average Price (2021-2032)
  6. 2.3 Second-Generation Antipsychotics by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Selective Dopamine Receptor Antagonists
  9. 2.3.3 Multi Receptor Acting Drugs
  10. 2.3.4 Dopamine Receptor Partial Agonists
  11. 2.3.5 5-Hydroxytryptamine And Dopamine Receptor Antagonists
  12. 2.4 Second-Generation Antipsychotics by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Adjuvant Treatment For Depression
  15. 2.4.3 Bipolar Disorder
  16. 2.4.4 Schizophrenia
  17. 2.4.5 Other Mental Illnesses
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Second-Generation Antipsychotics Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Second-Generation Antipsychotics Sales (units) of Manufacturers (2021-2026)
  3. 3.3 Global Second-Generation Antipsychotics Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Second-Generation Antipsychotics Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Second-Generation Antipsychotics Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Second-Generation Antipsychotics, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Second-Generation Antipsychotics, Product Type & Application
  8. 3.8 Global Manufacturers of Second-Generation Antipsychotics, Established Date
  9. 3.9 Global Second-Generation Antipsychotics Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chia Tai Tianqing Pharmaceutical
  2. 4.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 4.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 4.1.3 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  6. 4.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 4.2 Yangtze River Pharmaceutical Group
  8. 4.2.1 Yangtze River Pharmaceutical Group Company Information
  9. 4.2.2 Yangtze River Pharmaceutical Group Business Overview
  10. 4.2.3 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
  12. 4.2.5 Yangtze River Pharmaceutical Group Recent Developments
  13. 4.3 CSPC Pharmaceutical Group
  14. 4.3.1 CSPC Pharmaceutical Group Company Information
  15. 4.3.2 CSPC Pharmaceutical Group Business Overview
  16. 4.3.3 CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 CSPC Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
  18. 4.3.5 CSPC Pharmaceutical Group Recent Developments
  19. 4.4 Qilu Pharmaceutical
  20. 4.4.1 Qilu Pharmaceutical Company Information
  21. 4.4.2 Qilu Pharmaceutical Business Overview
  22. 4.4.3 Qilu Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Qilu Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  24. 4.4.5 Qilu Pharmaceutical Recent Developments
  25. 4.5 Novartis
  26. 4.5.1 Novartis Company Information
  27. 4.5.2 Novartis Business Overview
  28. 4.5.3 Novartis Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Novartis Second-Generation Antipsychotics Product Portfolio
  30. 4.5.5 Novartis Recent Developments
  31. 4.6 Merck
  32. 4.6.1 Merck Company Information
  33. 4.6.2 Merck Business Overview
  34. 4.6.3 Merck Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Merck Second-Generation Antipsychotics Product Portfolio
  36. 4.6.5 Merck Recent Developments
  37. 4.7 Luye Pharma Group
  38. 4.7.1 Luye Pharma Group Company Information
  39. 4.7.2 Luye Pharma Group Business Overview
  40. 4.7.3 Luye Pharma Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Luye Pharma Group Second-Generation Antipsychotics Product Portfolio
  42. 4.7.5 Luye Pharma Group Recent Developments
  43. 4.8 Roche
  44. 4.8.1 Roche Company Information
  45. 4.8.2 Roche Business Overview
  46. 4.8.3 Roche Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Roche Second-Generation Antipsychotics Product Portfolio
  48. 4.8.5 Roche Recent Developments
  49. 4.9 Livzon Pharmaceutical Group
  50. 4.9.1 Livzon Pharmaceutical Group Company Information
  51. 4.9.2 Livzon Pharmaceutical Group Business Overview
  52. 4.9.3 Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Livzon Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
  54. 4.9.5 Livzon Pharmaceutical Group Recent Developments
  55. 4.10 Eli Lilly
  56. 4.10.1 Eli Lilly Company Information
  57. 4.10.2 Eli Lilly Business Overview
  58. 4.10.3 Eli Lilly Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Eli Lilly Second-Generation Antipsychotics Product Portfolio
  60. 4.10.5 Eli Lilly Recent Developments
  61. 4.11 Chengdu Kanghong Pharmaceutical
  62. 4.11.1 Chengdu Kanghong Pharmaceutical Company Information
  63. 4.11.2 Chengdu Kanghong Pharmaceutical Business Overview
  64. 4.11.3 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  66. 4.11.5 Chengdu Kanghong Pharmaceutical Recent Developments
  67. 4.12 Pfizer
  68. 4.12.1 Pfizer Company Information
  69. 4.12.2 Pfizer Business Overview
  70. 4.12.3 Pfizer Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Pfizer Second-Generation Antipsychotics Product Portfolio
  72. 4.12.5 Pfizer Recent Developments
  73. 4.13 Hansoh Pharma
  74. 4.13.1 Hansoh Pharma Company Information
  75. 4.13.2 Hansoh Pharma Business Overview
  76. 4.13.3 Hansoh Pharma Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Hansoh Pharma Second-Generation Antipsychotics Product Portfolio
  78. 4.13.5 Hansoh Pharma Recent Developments
  79. 4.14 Hisun Pharmaceutical
  80. 4.14.1 Hisun Pharmaceutical Company Information
  81. 4.14.2 Hisun Pharmaceutical Business Overview
  82. 4.14.3 Hisun Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Hisun Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  84. 4.14.5 Hisun Pharmaceutical Recent Developments
  85. 4.15 Nhwa Pharmaceutical
  86. 4.15.1 Nhwa Pharmaceutical Company Information
  87. 4.15.2 Nhwa Pharmaceutical Business Overview
  88. 4.15.3 Nhwa Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Nhwa Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  90. 4.15.5 Nhwa Pharmaceutical Recent Developments
  91. 4.16 AbbVie
  92. 4.16.1 AbbVie Company Information
  93. 4.16.2 AbbVie Business Overview
  94. 4.16.3 AbbVie Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 AbbVie Second-Generation Antipsychotics Product Portfolio
  96. 4.16.5 AbbVie Recent Developments
  97. 4.17 Sumitomo Dainippon Pharma
  98. 4.17.1 Sumitomo Dainippon Pharma Company Information
  99. 4.17.2 Sumitomo Dainippon Pharma Business Overview
  100. 4.17.3 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product Portfolio
  102. 4.17.5 Sumitomo Dainippon Pharma Recent Developments
  103. 4.18 Otsuka Pharmaceutical
  104. 4.18.1 Otsuka Pharmaceutical Company Information
  105. 4.18.2 Otsuka Pharmaceutical Business Overview
  106. 4.18.3 Otsuka Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Otsuka Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  108. 4.18.5 Otsuka Pharmaceutical Recent Developments
  109. 4.19 Johnson And Johnson
  110. 4.19.1 Johnson And Johnson Company Information
  111. 4.19.2 Johnson And Johnson Business Overview
  112. 4.19.3 Johnson And Johnson Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Johnson And Johnson Second-Generation Antipsychotics Product Portfolio
  114. 4.19.5 Johnson And Johnson Recent Developments
  115. 4.20 Ipsen
  116. 4.20.1 Ipsen Company Information
  117. 4.20.2 Ipsen Business Overview
  118. 4.20.3 Ipsen Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Ipsen Second-Generation Antipsychotics Product Portfolio
  120. 4.20.5 Ipsen Recent Developments
5 Global Second-Generation Antipsychotics Market Scenario by Region
  1. 5.1 Global Second-Generation Antipsychotics Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Second-Generation Antipsychotics Sales by Region: 2021-2032
  3. 5.2.1 Global Second-Generation Antipsychotics Sales by Region: 2021-2026
  4. 5.2.2 Global Second-Generation Antipsychotics Sales by Region: 2027-2032
  5. 5.3 Global Second-Generation Antipsychotics Revenue by Region: 2021-2032
  6. 5.3.1 Global Second-Generation Antipsychotics Revenue by Region: 2021-2026
  7. 5.3.2 Global Second-Generation Antipsychotics Revenue by Region: 2027-2032
  8. 5.4 North America Second-Generation Antipsychotics Market Facts & Figures by Country
  9. 5.4.1 North America Second-Generation Antipsychotics Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Second-Generation Antipsychotics Sales by Country (2021-2032)
  11. 5.4.3 North America Second-Generation Antipsychotics Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Second-Generation Antipsychotics Market Facts & Figures by Country
  16. 5.5.1 Europe Second-Generation Antipsychotics Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Second-Generation Antipsychotics Sales by Country (2021-2032)
  18. 5.5.3 Europe Second-Generation Antipsychotics Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Second-Generation Antipsychotics Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Second-Generation Antipsychotics Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Second-Generation Antipsychotics Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Second-Generation Antipsychotics Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Second-Generation Antipsychotics Market Facts & Figures by Country
  41. 5.7.1 South America Second-Generation Antipsychotics Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Second-Generation Antipsychotics Sales by Country (2021-2032)
  43. 5.7.3 South America Second-Generation Antipsychotics Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Second-Generation Antipsychotics Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Second-Generation Antipsychotics Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Second-Generation Antipsychotics Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Second-Generation Antipsychotics Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Second-Generation Antipsychotics Sales by Type (2021-2032)
  2. 6.1.1 Global Second-Generation Antipsychotics Sales by Type (2021-2032) & (units)
  3. 6.1.2 Global Second-Generation Antipsychotics Sales Market Share by Type (2021-2032)
  4. 6.2 Global Second-Generation Antipsychotics Revenue by Type (2021-2032)
  5. 6.2.1 Global Second-Generation Antipsychotics Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Second-Generation Antipsychotics Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Second-Generation Antipsychotics Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Second-Generation Antipsychotics Sales by Application (2021-2032)
  2. 7.1.1 Global Second-Generation Antipsychotics Sales by Application (2021-2032) & (units)
  3. 7.1.2 Global Second-Generation Antipsychotics Sales Market Share by Application (2021-2032)
  4. 7.2 Global Second-Generation Antipsychotics Revenue by Application (2021-2032)
  5. 7.2.1 Global Second-Generation Antipsychotics Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Second-Generation Antipsychotics Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Second-Generation Antipsychotics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Second-Generation Antipsychotics Value Chain Analysis
  2. 8.1.1 Second-Generation Antipsychotics Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Second-Generation Antipsychotics Production Mode & Process
  5. 8.2 Second-Generation Antipsychotics Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Second-Generation Antipsychotics Distributors
  8. 8.2.3 Second-Generation Antipsychotics Customers
9 Global Second-Generation Antipsychotics Analyzing Market Dynamics
  1. 9.1 Second-Generation Antipsychotics Industry Trends
  2. 9.2 Second-Generation Antipsychotics Industry Drivers
  3. 9.3 Second-Generation Antipsychotics Industry Opportunities and Challenges
  4. 9.4 Second-Generation Antipsychotics Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst